Literature DB >> 21196112

Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy.

Michael D Jenkinson1, Brian Haylock, Aditya Shenoy, David Husband, Mohsen Javadpour.   

Abstract

Brain metastases constitute a significant disease burden and have a major impact on morbidity and mortality. This review discusses the relative merits of open surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS), which have been used alone and in combination with varying degrees of success for the treatment of newly diagnosed brain metastasis. Treatment aims to provide disease control with a good quality of life, although prolonged survival may not always be achieved. Decision to treat is based on several prognostic factors including age, performance status and control of the primary cancer. The recently developed disease-specific graded prognostic assessment (DS-GPA) scales can aid in clinical decision making for individual patients. Whole brain radiotherapy remains the mainstay of treatment and provides effective palliation. Omission of WBRT results in worse local and distant control, though not survival. Local tumour control can be achieved by either resection of stereotactic radiosurgery (SRS). In long-term survivors WBRT may cause cognitive decline and SRS is being explored as an alternative method of disease control. Increasingly, quality of life and neuro-cognitive function are being used as end-points in clinical trials.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21196112     DOI: 10.1016/j.ejca.2010.11.033

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  37 in total

1.  Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study.

Authors:  Olcay Cem Bulut; Katja Lindel; Henrik Hauswald; Regine Brandt; Frederick Klauschen; Janina Wolf; Thomas Wolf; Peter K Plinkert; Christian Simon; Wilko Weichert; Albrecht Stenzinger
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-29       Impact factor: 2.503

2.  Treatment of brain oligometastases with hypofractionated stereotactic radiotherapy utilising volumetric modulated arc therapy.

Authors:  Jeremy Croker; Benjamin Chua; Anne Bernard; Maryse Allon; Matthew Foote
Journal:  Clin Exp Metastasis       Date:  2015-10-19       Impact factor: 5.150

3.  Prognostic factors in patients treated with stereotactic image-guided robotic radiosurgery for brain metastases: a single-center retrospective analysis of 223 patients.

Authors:  Antonio Pontoriero; Alfredo Conti; Giuseppe Iatì; Stefania Mondello; Dario Aiello; Carmen Rifatto; Edoarda Risoleti; Micol Mazzei; Francesco Tomasello; Stefano Pergolizzi; Costantino De Renzis
Journal:  Neurosurg Rev       Date:  2016-04-23       Impact factor: 3.042

4.  Brain metastases from stomach cancer - The role of different treatment modalities and efficacy of palliative radiotherapy.

Authors:  Malgorzata Kraszkiewicz; Jerzy Wydmanski
Journal:  Rep Pract Oncol Radiother       Date:  2014-08-28

5.  Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis.

Authors:  Teneille E Gofton; Jerome Graber; Alan Carver
Journal:  J Neurooncol       Date:  2012-03-31       Impact factor: 4.130

6.  Hypofractionated stereotactic radiotherapy (hfSRT) after tumour resection of a single brain metastasis: report of a single-centre individualized treatment approach.

Authors:  Diana Steinmann; Bettina Maertens; Stefan Janssen; Martin Werner; Jörg Frühauf; Makoto Nakamura; Hans Christiansen; Michael Bremer
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-24       Impact factor: 4.553

7.  Validation of Recursive Partitioning Analysis and Diagnosis-Specific Graded Prognostic Assessment in patients treated initially with radiosurgery alone.

Authors:  Anna Likhacheva; Chelsea C Pinnix; Neil Parikh; Pamela K Allen; Nandita Guha-Thakurta; Mary McAleer; Erik P Sulman; Anita Mahajan; Almon Shiu; Dershan Luo; Max Chiu; Paul D Brown; Sujit S Prabhu; Eric L Chang
Journal:  J Neurosurg       Date:  2012-12       Impact factor: 5.115

8.  Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas.

Authors:  Pei-Fang Wu; Wen-Chang Huang; James Chih-Hsin Yang; Yen-Shen Lu; Jin-Yuan Shih; Shang-Gin Wu; Ching-Hung Lin; Ann-Lii Cheng
Journal:  J Neurooncol       Date:  2013-07-02       Impact factor: 4.130

Review 9.  Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG.

Authors:  Kathreena M Kurian; Michael D Jenkinson; Paul M Brennan; Robin Grant; Sarah Jefferies; Alasdair G Rooney; Helen Bulbeck; Sara C Erridge; Samantha Mills; Catherine McBain; Martin G McCabe; Stephen J Price; Silvia Marino; Erica Moyes; Wendy Qian; Adam Waldman; Babar Vaqas; Debbie Keatley; Peter Burchill; Colin Watts
Journal:  Neurooncol Pract       Date:  2017-08-30

10.  Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.

Authors:  Anna S Berghoff; Fabian Wolpert; Tim Holland-Letz; Romina Koller; Georg Widhalm; Brigitte Gatterbauer; Karin Dieckmann; Peter Birner; Rupert Bartsch; Christoph C Zielinski; Michael Weller; Matthias Preusser
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.